Drug Combination Details
| General Information of the Combination (ID: C13933) | |||||
|---|---|---|---|---|---|
| Name | Apigenin NP Info | + | Gemcitabine Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Pancreatic cancer
[ICD-11: 2C10]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | MIA PaCa-2 | CVCL_0428 | Pancreatic ductal adenocarcinoma | Homo sapiens | ||
| AsPC-1 | CVCL_0152 | Pancreatic ductal adenocarcinoma | Homo sapiens | |||
| In-vivo Model | Male BALB/c nude mice were subcutaneously inoculated with MiaPaca-2 cells (1*106 cells/mouse) cells in 1 mL of Matrigel. | |||||
| Experimental
Result(s) |
The combination of gemcitabine and apigenin enhanced anti-tumor efficacy through Akt and NF-kappa B activity suppression and apoptosis induction. | |||||
| Experiment 2 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Biological
Regulation |
Induction | Cell cycle arrest in S and G2/M phase | ||||
| In-vitro Model | AsPC-1 | CVCL_0152 | Pancreatic ductal adenocarcinoma | Homo sapiens | ||
| HPAF-II | CVCL_0313 | Pancreatic ductal adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Combination treatment with apigenin and gemcitabine inhibited pancreatic cancer cell growth via cell cycle arrest, down-regulation of the prosurvival factor pAkt, and induction of apoptosis. | |||||
